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Objective : We retrospectively evaluated the survival outcome of patients with brain metastasis from hepatocellular carcinoma (HCC).
Methods : Between 1991 and 2007, a total of 20 patients were diagnosed as having brain metastasis from HCC. The mean age of the patients
was 55 ± 13 years, and 17 (85.0%) were men. Seventeen (85.0%) patients had already extracranial metastases. The median time from diagnosis
of HCC to brain metastasis was 18.5 months. Fourteen (70.0%) patients had stroke-like presentation due to intracerebral hemorrhage (ICH). Ten
(50.0%) patients had single or solitary brain metastasis. Among a total of 34 brain lesions, 31 (91.2%) lesions had the hemorrhagic components. 
Results : The median survival time was 8 weeks (95% CI, 5.08-10.92), and the actuarial survival rates were 85.0%, 45.0%, 22.5%, and 8.4% at
4, 12, 24, and 54 weeks. Age < 60 years, treatment of the primary and/or extracranial lesions, and recurrent ICH were the possible prognostic
factors (p = 0.044, p < 0.001, and p = 0.111, respectively). The median progression-free survival (PFS) time was 3 months (95% CI, 0.95-5.05). 
Conclusion : The overall survival of the patients with brain metastasis from HCC was very poor with median survival time being only 8 weeks.
However, the younger patients less than 60 years and/or no extracranial metastases seem to be a positive prognostic factor.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a notorious cancer
due to its aggressive clinical course and short survival time
in Asian populations, and over the past two decades it has
been a growing public health problem worldwide because
its incidence has substantially increased5,7,21,22). Therefore,
HCC currently ranks as the fifth most common type of
cancer in men worldwide, though it was formerly considered
to be a rare disease in Western and European countries6,7,22).
In addition, recent therapeutic advances in surgical techni-
que, transarterial chemoembolization (TACE), and various
chemotherapeutic agents have contributed to the improved
survival rate in these patients, which has increased the inci-
dence of extrahepatic metastases1,10).
However, even in the endemic areas, brain metastasis from
HCC is so rare that the incidence was reported to be only
about 0.2%10). Only few exclusive studies reported that the
prognosis is so poor when HCC spreads into the intracra-
nial structures, including the skull and/or the brain, that
the median survival time was just 1-2 months1,3). Thus, the
authors performed this retrospective study in an effort to
identify both the overall survival time and the prognostic
factors for patients with brain metastasis from HCC.
MATERIALS AND METHODS
Patients and inclusion criteria
Between 1991 and 2007, a total of 20 patients were diag-
nosed as having brain metastasis from HCC. In this study,
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we included only the patients who had one or more brain
parenchymal lesions with rim enhancement, homogeneous
enhancement, or lobar hemorrhage suggesting neoplastic
hemorrhage with enhancing solid portion (Fig. 1C) rather
than hypertensive hemorrhage on brain computed tomo-
graphy (CT) scan or magnetic resonance (MR) scan in the
setting of histologically-confirmed HCC.
All patients underwent surgical resection or biopsy for the
liver mass, and the histological confirmation of the HCC
diagnosis was made in every case. All patients had had a his-
tory of liver cirrhosis after hepatitis B virus (HBV) infection
in 17 (85.0%) patients, after HCV infection in 2 (10.0%),
and after Clonorchis sinensis infection in one (5.0%). Brain
lesion was histologically diagnosed as a metastasis from
HCC in 7 (35.0%) patients, and the remaining 13 (65%)
patients whose diagnosis of brain lesion was made only radio-
logically had the evidence of neoplastic hemorrhage with
enhancing solid portion on MR images, suggesting a metas-
tasis from HCC, and/or had multiple extracranial metastases
in the lung, bone, and/or lymph nodes.
During the aforementioned period, a total of 41,400 pati-
ents were diagnosed as having HCC in our institute. Thus,
the incidence of brain metastasis from HCC was 0.05%.
Data collection and treatments for brain 
metastasis
All patient data were based on information contained in
hospital charts and radiological studies and were collected
in accordance with the case record form approved by the
institutional review board. Clinical data, including informa-
tion on age, Child-Pugh classification12,19), the level of alpha-
fetoprotein (AFP), the Eastern Cooperative Oncology
Group (ECOG) performance status15), the RTOG recursive
partitioning analysis (RPA) classification8), radiological
characteristics, treatment modality,
and survival were collected. Any data
that were missing from the medical
records due to follow-up loss were ob-
tained through a telephone interview
with the patient or with his or her rela-
tives, if deceased, after obtaining their
permission.
The initial treatment modalily and/
or the adjuvant treatment for brain
lesions was selected after our consider-
ing the patients’ will and/or patients’
status, such as presence of intracere-
bral hemorrhage (ICH) and its mass
effect, possibility of surgical resection,
and medical and functional condition
of the patients. Conventional radiotherapy had been mainly
selected as an initial or adjuvant treatment according to the
physician’s decision before 1998, when a Gamma Knife
unit was installed in our institute. 
Whole brain radiotherapy and/or Gamma Knife 
radiosurgery
Whole brain radiotherapy (WBRT) was initiated 1-2
weeks after surgery or diagnosis of brain metastasis with a
total dose of 30-45 Gy and 3.0 Gy per fraction with five
fractions per week. WBRT or Gamma Knife radiosurgery
(GKS) was used only as an adjuvant treatment after failure
of each modality.
GKS was performed using the Leksell Gamma Knife
(Elekta Instrument AB, Stockholm, Sweden) model B or
C. Treatment planning was performed using thin-sliced
MR images. The radiosurgery isodose, maximum dose, and
marginal dose were decided based on contrast-enhanced
lesion volume, calculated during dose planning with the
best-fit isodose method. Therefore, we prescribed about 20
Gy for small lesions less than 6 cm3 in volume, and reduced
the dose gradually to 10 Gy according to increase of the
lesion volume. The treatments were designed to deliver 45-
70% of the maximum dose at the margins of the lesion.
Statistical analysis
The overall survival and prognostic factors were analyzed.
Overall survival was defined as the interval between the
date of diagnosis of brain metastasis and the data of death.
The Kaplan-Meier method was used to estimate the overall
survival distributions. A log-rank test was used to test for
differences in overall survival between the groups according
to a given covariate. All covariates were analyzed in the
form of a categorical variable, such as age > 60 years, AFP >
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Fig. 1. A : Gradient echo magnetic resonance (MR) image showing a hemorrhagic component in the
tumor as lesions with low signal intensities. B : A large intracerebral hemorrhage (ICH) is identified on
computed tomography scan of a patient with sudden headache and visual disturbance. The area near
the midline in the hematoma with lower density than hematoma is brain metastasis from hepatocellular
carcinoma. C : An ICH and edema around the heterogeneously enhancing mass on T1 gadolinium-
enhance MR image.
A B C
400 ng/mL, ECOG performance status 3/4 or not, and
RPA class 1/2 or not. The patients were also stratified into
two groups according to whether or not surgical resection
for brain metastasis was performed, and were stratified ac-
cording to whether or not treatment for the primary and/or
extracranial lesions was performed. To compare the distri-
bution of the binomial variables, the Mann-Whitney U test
were performed. All statistical analyses were performed at
an α level of 0.05, using SPSS version 12.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Clinical and radiological features
The mean age of the patients was 55 ± 13 years (range,
22-76), and 17 (85.0%) were men. In 14 (70.0%) patients,
brain metastasis was identified by work-up for neurological
symptoms during follow-up of HCC. Metastasis to the lung
and/or spine or para-aortic lymph nodes preceded brain
metastasis in 10 patients, and metastasis only to the para-
aortic lymph node and spine was identified before brain
metastasis in each one of two patients. In the remaining two
patients, there was no evidence of extracranial metastasis at
the time of brain metastasis. In six (30.0%) patients, neurol-
ogical symptoms were the first manifestation of HCC. The
median time from diagnosis of HCC to brain metastasis
was 18.5 months.
Five patients already had extracranial metastases disco-
vered concurrently with development of neurological symp-
toms; four patients with lung and/or bone metastases and
one with only bone metastasis. The rest one patient had no
extracranial metastasis. Thus, overall 17 (85.0%) patients
had already extracranial metastases. Only 3 (15.0%) had no
evidence of extracranial metastasis after a thorough systemic
work-up, and interestingly one female patient of them did
not have any evidence of a viable tumor even in the liver and
survived 165 weeks, the longest survival time of this series.
Presenting symptoms were hemiparesis and/or headache
in 9 (45.0%) patients, visual field cut and headache in 5
(25.0%) patients, only headache in 3 (15.0%), and loss of
consciousness in 3 (15.0%). Fourteen (70.0%) patients had
stroke-like presentation due to ICH, and among them 12
patients were those whose brain metastases were identified
during follow-up of HCC (p = 0.022).
At the time of brain metastasis, the severity of liver cirrho-
sis was classified as Child-Pugh grade A12,19) in 16 (80.0%)
patients and B in the remaining 4 (20.0%) patients. None
of the patients were classified as grade C, and no patient
had a delayed prothrombin time. Among 18 patients whose
serum AFP level was evaluated at the time of diagnosis of
brain metastasis from HCC, the serum AFP level was within
normal rage (0-20 ng/mL) in 6 (33.3%) patients.
Ten (50.0%) patients had single or solitary brain metas-
tasis and the remaining half of the patients had multiple
lesions up to three. Among a total of 34 brain lesions, 15
(44.1%) were located in the parieto-occipital area, 12
(35.3%) in the frontal lobe, 4 (11.8%) in the cerebellar
hemisphere, and each one (2.9%) of the remaining three le-
sions in the temporal lobe, middle cerebellar peduncle, and
the head of the caudate nucleus. The mean longest diame-
ter of brain lesions defined as contrast-enhancing portion
on MR images was 21 ± 13 mm (range, 4-50). The hemorr-
hagic components in or near the mass were radiologically
identified in 31 (91.2%) lesions on the gradient echo MR
images and/or CT scan (Fig. 1). The characteristics of the
patients and the details of their management are summa-
rized in Table 1.
Treatments
Seven (35.0%) patients underwent surgical resection of
brain metastasis and/or ICH; three patients had complete
resection and four patients had incomplete resection based
on radiological findings after surgery; CT scan in three pa-
tients and MR imaging in four. The cause of incomplete
resection in four patients was a profound bleeding from the
metastatic lesions during surgery. Then, they were treated
with WBRT in 6 patients and GKS in one patient. Among
them, one patient underwent one cycle of chemotherapy
using 5-fluorouracil and mitomycin (FM#1) for treatment
of primary and/or extracranial lesions, and one had no
evidence of disease after thorough systemic work-up at the
time of brain metastasis.
Eleven (55.0%) patients were initially treated with radia-
tion, such as GKS in 7 patients and WBRT in 4 patients.
Among them, five patients underwent treatments for their
primary and/or extracranial lesions; two patients were treated
with one session of TACE, one with two sessions of TACE
and FM#1, one with two cycles of chemotherapy using 5-
fluorouracil, adriamycin, and mitomycin, one with FM#4
and radiotherapy to the lung metastases (3,750 cGy in 15
fractions). The remaining two (10.0%) patients (patient
No. 11 and 20) refused any treatments for their primary
lesion and brain metastases.
Overall survival and progression free survival
As of January 2, 2008, a total of 18 (90.0%) patients died,
and two (10.0%) were still alive with progressive disease in
the brain parenchyma. In terms of the cause of death as
determined using the protocol described by Patchell et al.17),
there were 10 (50.0%) neurologic deaths and 8 (40.0%)
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systemic deaths. The median sur-
vival time was 8 weeks (95% CI,
5.08-10.92), and the actuarial survi-
val rates were 85.0%, 45.0%, 22.5%,
and 8.4% at 4, 12, 24, and 54 weeks
(Fig. 2).
The patients younger than 60 years
had a longer median survival time
than the others [18 weeks (95% CI,
6.87-29.13) vs. 12 weeks (95% CI,
4.30-19.70); p = 0.044] (Fig. 3A).
The patients whose primary and/or
extracranial lesions were treated had
a significantly longer median survi-
val time that those without treat-
ment [54 weeks (95% CI, 27.31-
80.69) vs. 9 weeks (95% CI, 1.96-
16.05); p < 0.001] (Fig. 3B). Patients
with recurrent ICH after treatment
had a poorer median survival time
than that of those without it [5
weeks (95% CI, 0.20-9.80) vs. 16
weeks (95% CI, 10.569-21.44); p =
0.111] (Fig. 3C), however, the dif-
ference in survival time did not reach
the statistical significance. The pati-
ents treated with radiation only using
WBRT and/or GKS had a longer
median survival time (16 weeks;
95% CI, 9.93-22.07) than that of
those who underwent surgical resec-
tion of brain metastases followed by
adjuvant therapy (8 weeks; 95% CI,
0.30-15.70), however this difference
in survival time also did not reach
the statistical significance (p = 0.667).
Manifestation with ICH, RPA class
1/2 or not, liver function define by
Child-Pugh classification, AFP level
(> 400 ng/mL), and multiplicity of
the lesions also did not have a signi-
ficant effect on survival.
Seven (35.0%) patients died with-
out any follow-up imaging studies;
six patients died of very rapid pro-
gression of the neurological status,
and the remaining one patient died
of upper gastro-intestinal (GI) bleed-
ing. In three (23.1%) of 13 patients
with one or more follow-up imag-

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ing studies, new lesions appeared outside the treated areas,
and 5 (38.5%) patients had regrowth of the treated lesions.
The median progression-free survival (PFS) time was 3
months (95% CI, 0.95-5.05). The actuarial PFS rates were
69.2%, 49.5%, and 16.5% at 1, 3, and 5 months, respecti-
vely. The presence of extracranial metastases, AFP > 400
ng/mL, and the presence of multiple brain lesions showed
the negative association with PFS (p = 0.089, p = 0.187,
and p = 0.062, respectively), however, they all did not reach
the statistical significance.
Additional treatments and complications
Six (30.0%) patients had additional treatment for brain
metastases; one patient underwent repeated radiosurgery
for new lesions outside the initially treated lesion, four pati-
ents were treated with radiosurgery for progression of the
brain metastasis or the new lesions outside the first brain
lesion after WBRT, and the last one patient experienced sur-
gery due to the recurrent ICH during WBRT after incom-
plete surgical resection.
No patients among 4 patients who underwent chemothe-
rapy experienced hematologic toxicities assessed using World
Health Organization common toxicity criteria version 2.0.
Six (30.0%) patients experienced recurrent ICH during
follow-up period; four patients among them died or under-
went repeat surgery due to recurrent ICH, and the remain-
ing two patients were treated conservatively. The majority
of recurrent ICHs developed within 2 weeks (4 days-8
weeks) after diagnosis of brain metastasis from HCC. Three
(15.0%) patients experienced aggravation of edema around
the brain lesion resulted in aggravation or development of
hemiparesis after WBRT and/or GKS. Three (15.0%) pati-
ents experienced GI bleeding during the follow-up period
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Fig. 2. Kaplan-Meier estimates of overall survival in the whole series (n =
20). The median survival time is 8 weeks (95% CI, 5.08-10.92), and the
actuarial survival rates are 85.0%, 45.0%, 22.5%, and 8.4% at 4, 12, 24, and
54 weeks.
Fig. 3. Kaplan-Meier estimates to test for differences in overall survival
between groups according to a given covariate using a log-rank test. A : The
patients younger than 60 years show a longer median survival time than
those older. [18 weeks (95% CI, 6.87-29.13) vs. 12 weeks (95% CI, 4.30-
19.70); p = 0.044]. B : The patients whose primary and/or extracranial
lesions were treated show a significantly longer median survival time that
those without treatment for the primary and/or extracranial lesions [54 weeks
(95% CI, 27.31-80.69) vs. 9 weeks (95% CI, 1.96-16.05); p < 0.001]. ‘syst.
Ds’ in the figure means the primary and/or extracranial lesions. C : Patients
with recurrent ICH after treatment show a poorer median survival time than
that of those without it [5 weeks (95% CI, 0.20-9.80) vs. 16 weeks (95% CI,




and were treated with endoscopic esophageal varix ligation.
And, each one of other three patients was treated due to he-
patitis after herb medication, hepatic encephalopathy, and
pneumonia, which were not directly related with treatments.
DISCUSSION
Though brain metastasis from HCC is a rare occurrence
even in the endemic areas, it may become a major health
problem in the near future due to the increasing incidence
of HCC, especially in the western and European countries,
and the prolonged survival due to the recent development
of advanced therapeutic techniques5,7,10,11,20-22). And, the
incidence of brain metastases from HCC seems to be more
higher than the previous estimations of 0.26% of the study
of Chang et al.1) considering the report of 2.2% in Japanese
autopsy series14).
Clinical and radiological features
In the present study, overall 17 (85.0%) patients already
had extracranial metastases to the lung, bone, and/or regional
lymph nodes at the time of diagnosis of brain metastasis
from HCC. Thus, brain metastasis from HCC seems to
develop at the end stage of disease progression of HCC
with dismal 5-year survival rate of less than 5 percent7).
Accordingly, the overall survival was very poor that the me-
dian survival time was only 8 weeks, and the actuarial sur-
vival rate was approximately 8% at one year. These findings
may suggest that a more effective therapy for systemic
HCC is required before any progress will be made with
brain metastases.
Such a poor survival outcome may also result from some
characteristic features of HCC brain metastasis. One of the
noticeable features is that brain metastasis from HCC had a
tendency of bleeding as in the previous reports1,2,4,9,10,13,14,16,18,21),
though no patients were classified as Child-Pugh grade C,
and had a delayed prothrombin time in this study. Thus,
70.0% of the patients had stroke-like presentation due to
tumor bleeding, and over 90% of the lesions had the he-
morrhagic components in or near the mass on MR images
and/or CT scan. In addition, six (42.9%) of 14 patients
who had presented with overt ICH experienced recurrent
bleeding from the tumors after treatments, which resulted
in fatal outcomes in those patients. This high rate of ICH
after treatments seemed to mainly result from the incom-
plete resection of the tumor in the patients who experienced
surgical resection and also was partly caused by the insuffi-
cient liver function that alters the hemostasis. Furthermore,
because the majority of the lesions were located near the
sensory-motor cortex, complete surgical resection of the
lesions were difficult and bleeding from the tumor had
usually resulted in neurological deficits and functional dec-
line of the patients, which made those patients not being
eligible for further adjuvant treatments.
Prognostic factors for overall survival
Age less than 60 years and treatments for the primary and
systemic extracranial metastases seems to be positively asso-
ciated with overall survival of the patients with brain metas-
tasis from HCC. This result may be in accordance with
those of the studies dealing with patients with brain metas-
tasis from other primary sites, such as lung, breast, kidney,
colon, and so on; however, there may be some possible con-
founding variables in this result, such as the functional status
of the patients and the state of the systemic disease, includ-
ing the state of intrahepatic primary tumor and extracranial
metastasis. Namely, treatments for the primary and systemic
extracranial metastases might be possible only for the
patients with relatively limited extent of disease and favora-
ble general condition. Nevertheless, we did not perform the
multivariate analysis to correct the possible confounding
variables because its statistical power was expected to be low
due to the small sample size.
One of the noticeable findings about brain metastasis
from HCC is that it has a tendency of bleeding, and it can
rebleed after treatment. In fact, recurrent bleeding from tu-
mor itself is one of the possible prognostic factors found in
this study, though it did not reach the statistical signifi-
cance. However, it was most problematic event during mana-
gement of patients with brain metastasis from HCC. In
addition, the cause of 4 deaths among 10 neurological deaths
was recurrent tumor bleeding (Table 1). Thus, recurrent
tumor bleeding seems to be the only evident cause of neuro-
logic death after treatment of brain metastasis from HCC.
Such a tendency of bleeding may be due to the patholo-
gical feature of brain metastasis of HCC of a trabecular or
sinusoidal pattern and interspersed vascular channels21).
Considering that all four patients with incomplete surgical
resection experienced recurrent ICH during or immediately
after adjuvant WBRT, complete surgical resection should
be obtained. If there are remnant tumors or unresectable
lesions, GKS seems to be more useful than WBRT in terms
of the time necessary for completion of each modality con-
sidering rapid progression of the neurological status and
relatively early rebleeding from brain metastasis though it is
obscure for GKS to prevent the recurrent bleeding and tu-
mor progression rather than other modalities. However, one
of the most important findings of this study is that decision
of any treatments including surgical resection, WBRT,
GKS, and chemotherapy should be cautiously made in
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selected patients, especially without evidence of extracranial
metastases and/or any viable tumor in the liver, considering
the poor clinical course and short-survival time in patients
with brain metastases from HCC, suggesting no response
to any treatments used in this study. 
CONCLUSION
The overall survival of the patients with brain metastasis
from HCC was very poor with median survival time being
only 8 weeks, and the actuarial survival rate was approxi-
mately 8% at one year. Recurrent bleeding from tumor is
one of the most problematic events in management of
patients with brain metastasis from HCC. However, the
younger patients less than 60 years and/or no extracranial
metastases seem to be a positive prognostic factor.
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